- Home
- AMRN vs BWAY Comparison
AMRN vs BWAY Comparison
Compare AMRN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMRN | BWAY |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 337.9M |
| IPO Year | 1993 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AMRN | BWAY |
|---|---|---|
| Price | $14.17 | $17.17 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $23.50 |
| AVG Volume (30 Days) | ★ 83.6K | 59.5K |
| Earning Date | 10-29-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | ★ $226,733,000.00 | $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ N/A | $52.44 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $7.08 | $7.84 |
| 52 Week High | $20.90 | $18.18 |
Technical Indicators
Market Signals| Indicator | AMRN | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 56.31 |
| Support Level | $13.64 | $16.75 |
| Resistance Level | $14.67 | $18.18 |
| Average True Range (ATR) | 0.73 | 0.76 |
| MACD | -0.14 | 0.06 |
| Stochastic Oscillator | 20.10 | 74.69 |
Price Performance
Historical ComparisonAbout AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.